Literature DB >> 34203869

Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines.

Laia Gorchs1, Helen Kaipe1,2.   

Abstract

Less than 10% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) survive 5 years or more, making it one of the most fatal cancers. Accumulation of T cells in pancreatic tumors is associated with better prognosis, but immunotherapies to enhance the anti-tumor activity of infiltrating T cells are failing in this devastating disease. Pancreatic tumors are characterized by a desmoplastic stroma, which mainly consists of activated cancer-associated fibroblasts (CAFs). Pancreatic CAFs have emerged as important regulators of the tumor microenvironment by contributing to immune evasion through the release of chemokines, cytokines, and growth factors, which alters T-cell migration, differentiation and cytotoxic activity. However, recent discoveries have also revealed that subsets of CAFs with diverse functions can either restrain or promote tumor progression. Here, we discuss our current knowledge about the interactions between CAFs and T cells in PDAC and summarize different therapy strategies targeting the CAF-T cell axis with focus on CAF-derived soluble immunosuppressive factors and chemokines. Identifying the functions of different CAF subsets and understanding their roles in T-cell trafficking within the tumor may be fundamental for the development of an effective combinational treatment for PDAC.

Entities:  

Keywords:  T cells; cancer-associated fibroblasts (CAFs); chemokines; immune checkpoint inhibitors; pancreatic ductal adenocarcinoma (PDAC); tumor microenvironment

Year:  2021        PMID: 34203869     DOI: 10.3390/cancers13122995

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  10 in total

Review 1.  Targeting KRAS in pancreatic cancer: new drugs on the horizon.

Authors:  Sahar F Bannoura; Md Hafiz Uddin; Misako Nagasaka; Farzeen Fazili; Mohammed Najeeb Al-Hallak; Philip A Philip; Bassel El-Rayes; Asfar S Azmi
Journal:  Cancer Metastasis Rev       Date:  2021-09-09       Impact factor: 9.237

Review 2.  The role of pyroptosis in modulating the tumor immune microenvironment.

Authors:  Jinxiang Wu; Lei Wang; Jianwei Xu
Journal:  Biomark Res       Date:  2022-06-23

Review 3.  The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy.

Authors:  Yu-Hsuan Hung; Li-Tzong Chen; Wen-Chun Hung
Journal:  Biomedicines       Date:  2022-04-18

Review 4.  Cell Lineage Infidelity in PDAC Progression and Therapy Resistance.

Authors:  Antonia Malinova; Lisa Veghini; Francisco X Real; Vincenzo Corbo
Journal:  Front Cell Dev Biol       Date:  2021-12-02

Review 5.  Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment.

Authors:  Jeong-Yeon Mun; Sun-Hee Leem; Jun Ho Lee; Hyuk Soon Kim
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

6.  Chemokine Receptor Expression on T Cells Is Modulated by CAFs and Chemokines Affect the Spatial Distribution of T Cells in Pancreatic Tumors.

Authors:  Laia Gorchs; Marlies Oosthoek; Tülay Yucel-Lindberg; Carlos Fernández Moro; Helen Kaipe
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

7.  STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer.

Authors:  Julia E Lefler; Catherine B MarElia-Bennett; Katie A Thies; Blake E Hildreth; Sudarshana M Sharma; Jason R Pitarresi; Lu Han; Caroline Everett; Christopher Koivisto; Maria C Cuitino; Cynthia D Timmers; Elizabeth O'Quinn; Melodie Parrish; Martin J Romeo; Amanda J Linke; G Aaron Hobbs; Gustavo Leone; Denis C Guttridge; Teresa A Zimmers; Gregory B Lesinski; Michael C Ostrowski
Journal:  Life Sci Alliance       Date:  2022-07-08

8.  Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.

Authors:  Hiroyuki Araki; Hiroshi Tazawa; Nobuhiko Kanaya; Yoshinori Kajiwara; Motohiko Yamada; Masashi Hashimoto; Satoru Kikuchi; Shinji Kuroda; Ryuichi Yoshida; Yuzo Umeda; Yasuo Urata; Shunsuke Kagawa; Toshiyoshi Fujiwara
Journal:  Mol Ther Oncolytics       Date:  2022-09-13       Impact factor: 6.311

Review 9.  PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

Authors:  Shruthi Narayanan; Silve Vicent; Mariano Ponz-Sarvisé
Journal:  Front Cell Dev Biol       Date:  2021-12-10

Review 10.  Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance.

Authors:  Pradip De; Jennifer Aske; Raed Sulaiman; Nandini Dey
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.